AUA: Pandemic Disruptions Impacted One in Four Prostate, Bladder Cancer Patients
Changes, delays, and cancellation of cancer treatment and ancillary care reported.
Prostate Cancer
Trials Supporting Cancer Drug Approvals Lack Information on Gender
Of more than 100 studies used to support drug approvals, none reported information on the gender of participants.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Proton Beam Therapy Increasingly Used to Treat Cancers, Even When Evidence of Effectiveness Is Lacking
The use of proton beam therapy (PBT) increased between 2004 and 2018, particularly for cancers in which the effectiveness of PBT is still under investigation.
Orteronel Does Not Improve Overall Survival in Prostate Cancer
Orteronel is likely not effective when compared with recently approved agents, according to researchers.
Racial Differences Seen for Use of Proton Beam Therapy
Disparities greatest most recently and for cancers for which PBT is the recommended radiation therapy modality.
How Men With mCRPC Interpret Signs, Symptoms in Uncertain Illness Situations
Researchers sought to understand how men with prostate cancer interpret the signs and symptoms of their disease and treatment in relation to their prognosis.
Prostate Cancer Biopsy, Diagnoses Down During the Pandemic
However, there were no statistically significant changes in rates by race.
DXA Screening Rate Low Among Older Men Initiating Prostate Cancer ADT
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
Camcevi Now Available for Advanced Prostate Cancer Treatment
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...